期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉西他滨联合顺铂治疗晚期非小细胞肺癌临床观察 被引量：1

Gemcitabine combined with cisplatin regimen in patients with advanced none small cell lung cancer
暂未订购
导出
摘要 目的:观察吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌的临床疗效和不良反应。方法:吉西他滨1000～1250mg/m2,30min内滴完,第1、8天给药,顺铂70mg/m2,静滴,第8天吉西他滨后给药,21天为1周期。分别化疗2～6周期后按WHO标准评价疗效和不良反应。结果:入组30例均可评价疗效,部分缓解(PR)13例,稳定(SD)14例,进展(PD)3例,近期有效率43.3%,中位疾病进展时间(TTP)为6.2个月。1年生存率60.0%,中位生存期(MST)13.5个月。主要不良反应为骨髓抑制及恶心呕吐。结论:GP方案治疗晚期非小细胞肺癌疗效较好,不良反应轻,多数患者耐受良好,值得推广应用。 Objective: To evaluate the efficacy and toxicity of gemcitabine combined with cisplatin (GP) regimen in patients with advanced none small cell lung cancer(NSCLC). Methods: Gemcitabine 1 000-1 250 mg/m2 iv 30 min, d1,8 and cisplatin 70 mg/m2 iv d8 after gemcitabine, and repeated every 21 days. Results: All 30 cases were available for objective response: PR 13 cases, SD 14 cases and PD 3 cases. The overall response rates (ORR) was 43.3%, 1-year-survival rate was 60.0%, the mTTP and mST was 6.2 m and 13.5 m respectively. The main toxicities were bone marrow suppression and nausea/vomiting. Conclusion: GP regimen is a high response regimen for advanced NSCLC with well-tolerated toxicity, which can be practised safely.
作者 陆明洁 金时代 卢凯华 刘平 束永前 巴一
机构地区 南京医科大学第一附属医院肿瘤中心
出处 《南京医科大学学报（自然科学版）》 CAS CSCD 北大核心 2005年第7期501-503,共3页 Journal of Nanjing Medical University(Natural Sciences)
基金 南京医科大学第一附属医院引进人才基金(NA0404)
关键词 非小细胞肺癌 吉西他滨 顺铂 化学治疗 none small cell lung cancer gemcitabine cisplatin chemotherapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Shepherd FA. Chemotherapy for non-small cell lung cancer:have we reached a new plateau[J]. Semin Oncol,1999,26(1 Suppl 4): 3-11.
  • 2樊正勤,卢凯华,朱陵君,刘连科,束永前.泰索帝联合顺铂治疗晚期非小细胞肺癌37例临床分析[J].南京医科大学学报（自然科学版）,2003,23(3):291-292. 被引量：1
  • 3于世英.吉西他滨用于非小细胞肺癌治疗的研究进展[J].中国癌症杂志,2001,11(4):367-370. 被引量：46
  • 4Miller VA, Ngkk, Grant SC, et al. New chemotherapeutic agents in NSCLC, in Lung Cancer [M]. the 2nd Edition.malden: Blackwell science, 1998. 217-234.
  • 5Bunn PA Jr. Triplet chemotherapy with gemcitabine,a platinum,and a third agent in the treatment of advanced non-small cell lung cancer [J]. Semin Oncol, 1999,26(1suppl 4): 25-30.
  • 6Gebbia V, Galetta D, Caruso M, et al. Gruppo Ocologico Italia Meridionale. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage ⅢB-Ⅳ non-small cell lung carcinoma: a prospective randomized phase Ⅲ trail of the Gruppo Oncologico Italia Meridionale[J]. Lung Cancer,2003,39(2): 179-189.
  • 7Rossi D, Graziano F, Catalano V, et al. A new cisplatin/gemcitabine schedule in locally advanced (ⅢB) and metastatic (Ⅳ) non-small cell lung cancer.relationship between dose-intensity and efficacy. A phase Ⅱ study[J].Anticancer Res,2002,22(5): 3087-3092.
  • 8蔡晓虹,陈萍,尹绪德,李秋.吉西他滨/卡铂和吉西他滨/顺铂方案治疗晚期非小细胞肺癌的疗效比较[J].中国肺癌杂志,2002,5(6):427-428. 被引量：12
  • 9Mazzanti P, Massacesi C, Rocchi MB ,et al. Randomized,muhicenter, phase Ⅱ study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer [J]. Lung Cancer,2003,41(1): 81-89.

二级参考文献23

  • 1[1]Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small-cell lung cancer[J]. Invest New Drugs,2000,18(1):29-42.
  • 2[2]Merimsky O, Wigler N, Greif Y, et al. Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small-cell lung cancer: a phase Ⅱ study[J]. Anticancer Drugs,2000,11(2):117-121.
  • 3[3]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2000,18(1):122-130.
  • 4[4]Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,1999,17(1):12-18.
  • 5[5]Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Project[J]. J Clin Oncol1999,17(11):3522-3530.
  • 6[6]Schiller J, Harrington D, Sandler A, et al. A randomized phase III trial of fourchemotherapy regimens in advanced non-samll cell lung cancer (NSCLC)[J]. Am Soc Clin Oncol,2000,19:1-1.
  • 7[7]Kroep JR, Peters GJ, van Moorsel CJA, et al. Gemcitabine-cisplatin: A schedule finding study[J]. Ann Oncol,1999,10(12):1503-1510.
  • 8[8]Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer[J]. J Clin Oncol,1999,17(7):2190-2197.
  • 9[9]Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung Cancer[J]. Ann Oncol1999,10(9):1043-1049.
  • 10[10]Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase Ⅱ trial[J]. J Clin Oncol,1999,17(3):914-920.

共引文献56

同被引文献10

  • 1Gebbia V,Oniga F,Agueli R,et al.Treatment of advanced non-small cell lung cancer:chemotherapy with or without cisplatin?[J].Ann Oncol,2006,17(Suppl 2):ii83-ii87.
  • 2Guarino AM,Miller DS,Arnold TS,et al.Platinate toxicity:past,present,and prospects[J].Cancer Treat Rep,1979,63(9-10):1475-1483.
  • 3Soria JC,Le Chevalier T.Is cisplatin still the best platinum compound in non-small-cell lung cancer?[J].Ann Oncol,2002,13(10):1515-1517.
  • 4Shyr Y,Choy H,Cmelak A,et al.Pattern of practice survey:non-small cell lung cancer in the US[J].Proc Am Soc Clin Oncol,1998,17:463a(abstr1778).
  • 5Lawrence H,Einhorn.Carboplatin versus cisplatin in lung cancer[J].Lung Cancer,2005,49(suppl 3,E21):S32-S35.
  • 6Rosell R,Gatzemeier U,Betticher DC,et al.Phase Ⅲ randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer.A cooperative multinational trial[J].Ann Oncol,2002,13(10):1539-1549.
  • 7Hotta K,Matsuo K,Ueoka H,et al.Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2004,22(19):3852-3859.
  • 8Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
  • 9蔡晓虹,陈萍,尹绪德,李秋.吉西他滨/卡铂和吉西他滨/顺铂方案治疗晚期非小细胞肺癌的疗效比较[J].中国肺癌杂志,2002,5(6):427-428. 被引量：12
  • 10史美祺,冯继锋,吴剑秋,沈波,潘良熹.每周吉西他滨联合顺铂第1或15天治疗晚期非小细胞肺癌近期疗效和毒副反应比较[J].中国肺癌杂志,2003,6(2):146-147. 被引量：1

引证文献1

二级引证文献3

南京医科大学学报（自然科学版）
2005年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部